Author

Lynn Pearson Butler

Institution: Emmes (United States)

Observed institutions: Novartis (Switzerland), Memorial Sloan Kettering Cancer Center, Kaiser Permanente, Bristol-Myers Squibb (United States), Cancer Research And Biostatistics, Emmes (United States), Leidos Biomedical Research Inc. (United States), Canadian Cancer Trials Group, Hamilton Health Sciences, Columbia University

OpenAlex ID: A5010952325

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

2021 · Sara M. Tolaney, Elizabeth Garrett-Mayer, et al. · Journal of Clinical Oncology · 231

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP

2023 · Jennifer K. Litton, Meredith M. Regan, et al. · Journal of Clinical Oncology · 117

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer

2018 · Andrew D. Seidman, Louise Bordeleau, et al. · Journal of Clinical Oncology · 30

NCI Breast Cancer Steering Committee Working Group (WG) report on meaningful and appropriate endpoints for clinical trials (CT) in metastatic breast cancer (MBC).

2017 · Andrew David Seidman, Meredith M. Regan, et al. · Journal of Clinical Oncology

A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer

2009 · Lynn Pearson Butler, Margaret M. Centenera, et al. · Adelaide Research & Scholarship (AR&S) (University of Adelaide)

Expression of the androgen receptor and its association with disease outcome in breast cancer

2006 · Niamh Murphy, Tina Bianco‐Miotto, et al. · Adelaide Research & Scholarship (AR&S) (University of Adelaide)

Works count: 6

Citation count: 378

H-index: 3

I10-index: 3